Debra Patt, MD, PhD, MBA, executive vice president at Texas Oncology, discusses her recent testimony to the US Senate on a case in which prior authorization caused a 6-week wait for a consult.
It is becoming harder for patients with cancer to receive the care they need within an appropriate time frame, said Debra Patt, MD, PhD, MBA, executive vice president at Texas Oncology, whose own experience has been bolstered by stories from other clinicians and the American Medical Association (AMA).
Transcript
You recently testified in the Senate about a prior authorization case in which you were told you would have to wait up to 6 weeks for a consult to treat your breast cancer patient with an innovative therapy. What have you heard from other oncologists since the AMA reported on this case?
Unfortunately, the burden of prior authorization is tremendous and growing. It substantially impacts patient care, frequently delaying and deterring appropriate patient care. What I testified about—which is a common practice—is that if you initially have denial from an insurance company in their PBM [pharmacy benefit manager] relationship, that they can go through a prior authorization process that should be rapid.
But the peer-to-peer review, what they told me was, “Dr Patt, we can't tell you when we're going to have someone call you for peer-to-peer review. But it will be sometime in the next 6 weeks, at 8 AM in the morning.” And so, I gave them my cell phone number. And I'm sort of at the mercy of when someone is going to call, not being able to schedule it. And that practice has become more and more prevalent.
I think it's a reflection of the vertical integration that we see in the payer markets between payers, [PBMs], and specialty pharmacy, and to some degree providers. What we've seen with this integration, the 6 top PBMs have about 80% of the market. And when that happens, there's an increase in formulary restrictions. You're going to get denials on things when they're not the preferred drug because there's formulary restrictions. And that's really related to preferential rebates in the insurance markets.
We're seeing in cancer care, where we have these new and novel innovative therapies, tremendous growth of this practice, and it makes it harder and harder for cancer patients to get the care that they need.
I have gotten a lot of feedback since my testimony, and that feedback from other doctors has been that they see the same thing, that they too have had patients for whom treatments weren't an option, because they had to wait an inappropriate amount of time for peer-to-peer review. The prior auth process delayed and deterred appropriate care, and that the natural consequence was that patients had worse cancer morbidity and mortality.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
2 Commerce Drive
Cranbury, NJ 08512